NAFLD, the most prevalent liver disease, affects approximately 25% of the global population (1.2 billion people), including 188 million in India. Left untreated, NAFLD can progress to non-alcoholic ...

Researchers from Columbia University and the German Cancer Center have found that stellate cells—star-shaped liver cells long ...

Medically reviewed by Qin Rao, MD Metabolic dysfunction-associated steatohepatitis (MASH)—previously known as nonalcoholic ...

Rencofilstat has been shown to reduce liver fibrosis and hepatocellular carcinoma tumor burden ... granted Fast Track designation for rencofilstat for the treatment of NASH. That was followed in June ...

Roche’s Genentech unit bought Jecure Therapeutics and its portfolio of NLRP3 drugs in 2018, focusing on peripheral drugs for NASH, liver fibrosis, gout, inflammatory bowel disease, and ...

A case study on how DelveInsight helped a pharma client navigate the evolving metabolic dysfunction-associated steatohepatitis (MASH) landsca ...

NASH diagnostics consists of CK-18 total, CK-18 cleaved, adiponectin and resistin. NASH diagnostic panel consists of diabetes, gender, BMI, triglyceride and CK-18 total, CK-18 cleaved levels.